» Articles » PMID: 35844538

Preclinical Autoimmune Disease: a Comparison of Rheumatoid Arthritis, Systemic Lupus Erythematosus, Multiple Sclerosis and Type 1 Diabetes

Overview
Journal Front Immunol
Date 2022 Jul 18
PMID 35844538
Authors
Affiliations
Soon will be listed here.
Abstract

The preclinical phase of autoimmune disorders is characterized by an initial asymptomatic phase of varying length followed by nonspecific signs and symptoms. A variety of autoimmune and inflammatory manifestations can be present and tend to increase in the last months to years before a clinical diagnosis can be made. The phenotype of an autoimmune disease depends on the involved organs, the underlying genetic susceptibility and pathophysiological processes. There are different as well as shared genetic or environmental risk factors and pathophysiological mechanisms between separate diseases. To shed more light on this, in this narrative review we compare the preclinical disease course of four important autoimmune diseases with distinct phenotypes: rheumatoid arthritis (RA), Systemic Lupus Erythematosus (SLE), multiple sclerosis (MS) and type 1 diabetes (T1D). In general, we observed some notable similarities such as a North-South gradient of decreasing prevalence, a female preponderance (except for T1D), major genetic risk factors at the HLA level, partly overlapping cytokine profiles and lifestyle risk factors such as obesity, smoking and stress. The latter risk factors are known to produce a state of chronic systemic low grade inflammation. A central characteristic of all four diseases is an on average lengthy prodromal phase with no or minor symptoms which can last many years, suggesting a gradually evolving interaction between the genetic profile and the environment. Part of the abnormalities may be present in unaffected family members, and autoimmune diseases can also cluster in families. In conclusion, a promising strategy for prevention of autoimmune diseases might be to address adverse life style factors by public health measures at the population level.

Citing Articles

Fibromyalgia, Depression, and Autoimmune Disorders: An Interconnected Web of Inflammation.

Sedda S, Cadoni M, Medici S, Aiello E, Erre G, Nivoli A Biomedicines. 2025; 13(2).

PMID: 40002916 PMC: 11853372. DOI: 10.3390/biomedicines13020503.


Deep learning-based prediction of autoimmune diseases.

Yang D, Peng X, Zheng S, Peng S Sci Rep. 2025; 15(1):4576.

PMID: 39920178 PMC: 11806040. DOI: 10.1038/s41598-025-88477-4.


Monitoring the follow-up of autoimmune chronic atrophic gastritis using parietal cell antibodies and markers of gastric function.

Panozzo M, Antico A, Bizzaro N J Transl Autoimmun. 2025; 10:100273.

PMID: 39917315 PMC: 11800024. DOI: 10.1016/j.jtauto.2025.100273.


The Prevalence of Autoimmune Diseases Among Children With Type I Diabetes Mellitus.

AlMoosa E, Al Ghadeer H, Alatiya J, Aldairam W, Alhamrani A, Alarbash A Cureus. 2025; 16(12):e76272.

PMID: 39845243 PMC: 11753791. DOI: 10.7759/cureus.76272.


Integrating electronic health records and GWAS summary statistics to predict the progression of autoimmune diseases from preclinical stages.

Wang C, Markus H, Diwadkar A, Khunsriraksakul C, Carrel L, Li B Nat Commun. 2025; 16(1):180.

PMID: 39747168 PMC: 11695684. DOI: 10.1038/s41467-024-55636-6.


References
1.
Kerkman P, Rombouts Y, van der Voort E, Trouw L, Huizinga T, Toes R . Circulating plasmablasts/plasmacells as a source of anticitrullinated protein antibodies in patients with rheumatoid arthritis. Ann Rheum Dis. 2013; 72(7):1259-63. DOI: 10.1136/annrheumdis-2012-202893. View

2.
Brink M, Hansson M, Mathsson L, Jakobsson P, Holmdahl R, Hallmans G . Multiplex analyses of antibodies against citrullinated peptides in individuals prior to development of rheumatoid arthritis. Arthritis Rheum. 2013; 65(4):899-910. DOI: 10.1002/art.37835. View

3.
Dabelea D, Bell R, DAgostino Jr R, Imperatore G, Johansen J, Linder B . Incidence of diabetes in youth in the United States. JAMA. 2007; 297(24):2716-24. DOI: 10.1001/jama.297.24.2716. View

4.
Pappas D, Nyberg F, Kremer J, Lampl K, Reed G, Horne L . Prevalence of cardiovascular disease and major risk factors in patients with rheumatoid arthritis: a multinational cross-sectional study. Clin Rheumatol. 2018; 37(9):2331-2340. DOI: 10.1007/s10067-018-4113-3. View

5.
Hurkmans E, van der Giesen F, Vliet Vlieland T, Schoones J, Van den Ende E . Dynamic exercise programs (aerobic capacity and/or muscle strength training) in patients with rheumatoid arthritis. Cochrane Database Syst Rev. 2009; (4):CD006853. PMC: 6769170. DOI: 10.1002/14651858.CD006853.pub2. View